enfortumab,pembrolizumab
astellas,seagen,merck
['ev-302', 'pembro', 'muc ,(-much)']
 both are great options in the us for cis-ineligible muc pts. individual pt s co-morbidities should guide the tx. await os data for ev-pembro from ev-302. would favor ev-pembro for pts with visceral mets.
so exciting to have multiple portions for our patients today!
GU oncologist, clinical trialist, Director GU Oncology @CleclinicMD Tweets my own, RT/Likes not active endorsement.